Our top pick for
Clovis Oncology Inc is a biotechnology business based in the US. Clovis Oncology shares (CLVS) are listed on the NASDAQ and all prices are listed in US Dollars. Clovis Oncology employs 429 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$4.34|
|52-week range||$4.06 - $11.10|
|50-day moving average||$4.53|
|200-day moving average||$5.28|
|Wall St. target price||$5.70|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.12|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-11)||0.70%|
|1 month (2021-09-16)||-5.86%|
|3 months (2021-07-16)||-14.06%|
|6 months (2021-04-16)||-27.42%|
|1 year (2020-10-16)||-27.61%|
|2 years (2019-10-18)||29.94%|
|3 years (2018-10-18)||29.96|
|5 years (2016-10-18)||32.93|
Valuing Clovis Oncology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Clovis Oncology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Clovis Oncology's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.13. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Clovis Oncology's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||$156.9 million|
|Gross profit TTM||$128.4 million|
|Return on assets TTM||-26.13%|
|Return on equity TTM||0%|
|Market capitalisation||$513.9 million|
TTM: trailing 12 months
There are currently 26.6 million Clovis Oncology shares held short by investors – that's known as Clovis Oncology's "short interest". This figure is 6.3% up from 25.0 million last month.
There are a few different ways that this level of interest in shorting Clovis Oncology shares can be evaluated.
Clovis Oncology's "short interest ratio" (SIR) is the quantity of Clovis Oncology shares currently shorted divided by the average quantity of Clovis Oncology shares traded daily (recently around 3.3 million). Clovis Oncology's SIR currently stands at 8.06. In other words for every 100,000 Clovis Oncology shares traded daily on the market, roughly 8060 shares are currently held short.
However Clovis Oncology's short interest can also be evaluated against the total number of Clovis Oncology shares, or, against the total number of tradable Clovis Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Clovis Oncology's short interest could be expressed as 0.22% of the outstanding shares (for every 100,000 Clovis Oncology shares in existence, roughly 220 shares are currently held short) or 0.2285% of the tradable shares (for every 100,000 tradable Clovis Oncology shares, roughly 229 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Clovis Oncology.
Find out more about how you can short Clovis Oncology stock.
We're not expecting Clovis Oncology to pay a dividend over the next 12 months.
Over the last 12 months, Clovis Oncology's shares have ranged in value from as little as $4.06 up to $11.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Clovis Oncology's is 1.7624. This would suggest that Clovis Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Clovis Oncology, Inc. , a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. It also provides lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3); and FAP-2286, a peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. The company distributes its products primarily through specialty pharmacies and distributors to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.